Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc Profil



BörsenkürzelALKS

Name des UnternehmensAlkermes Plc

IPO-datumJul 16, 1991

CEOPops (Richard F)

Anzahl der mitarbeiter1800

WertpapierartOrdinary Share

GeschäftsjahresendeJul 16

AddresseConnaught House

StadtDUBLIN

BörseNASDAQ OMX - NASDAQ BASIC

LandIreland

PostleitzahlD04 C5Y6

Telefon35317728000

Websitehttps://www.alkermes.com/

BörsenkürzelALKS

IPO-datumJul 16, 1991

CEOPops (Richard F)

Führungskräfte von Alkermes Plc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

65.39K

-6.12%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

65.39K

-6.12%

Mr. Brian P. McKeon

Independent Director

48.54K

+9.62%

Mr. Brian P. McKeon

Independent Director

48.54K

+9.62%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Alkermes Plc?



Die fünf größten Anteilseigner von Alkermes Plc sind: Mr. Richard F. Pops

Wie viele Institutionen halten Anteile an Alkermes Plc (ALKS)?



Mit Stand vom 2026Q1 halten 783 Institutionen Anteile an Alkermes Plc, mit einem Gesamtmarktwert von etwa 182.39M, was 109.43% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -11997400.00 gestiegen.

Was ist die größte Einnahmequelle von Alkermes Plc?



Am 2026Q1 erzielte das Geschäft mit VIVITROL für Alkermes Plc den höchsten Umsatz in Höhe von 124.45M, was 25.09% des Gesamtumsatzes entspricht.